Mediwound Ltd
F:M8W
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bewi ASA
OSE:BEWI
|
NO |
|
Magnite Inc
NASDAQ:MGNI
|
US |
Mediwound Ltd
Operating Income
Mediwound Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Income
-$25.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-2%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Income
$4.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Operating Income
-$7.5m
|
CAGR 3-Years
23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Operating Income
-$33m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Operating Income
₪14.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Operating Income
-₪7.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mediwound Ltd
Glance View
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
See Also
What is Mediwound Ltd's Operating Income?
Operating Income
-25.3m
USD
Based on the financial report for Dec 31, 2025, Mediwound Ltd's Operating Income amounts to -25.3m USD.
What is Mediwound Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-2%
Over the last year, the Operating Income growth was -30%. The average annual Operating Income growth rates for Mediwound Ltd have been -50% over the past three years , -23% over the past five years , and -2% over the past ten years .
